Clinical Trial Search

Primary: Cumulative Rate of Cervical Intraepithelial Neoplasia (CIN2+) (CIN2, CIN3 or Invasive Cancer) by Week 130 — 24.9; 26.5 Events per 100 persons

Primary: Number of Participants With Progressive Disease or Death Due to Any Cause at 3 Years — 55; 83; 149; 141 participants — p=0.029

Primary: Incidence of the Composite Endpoint of Human Papillomavirus (HPV) 16/18-related Cervical Intraepithelial Neoplasia (CIN) 2 or Worse in the Base Study — 0.0; 0.4…

Primary: HPV Identification — 95; 142; 78 biopsies

Primary: Number of Subjects Seroconverted for Anti-human Papilloma Virus 16 (Anti-HPV-16) and Anti-human Papilloma Virus 18 (Anti-HPV-18) Antibodies — 125; 2; 122; 3 Participants

Primary: Feasibility of Intravaginal Use 5-FU and Imiquimod on Alternating Weeks in Women With Biopsy Confirmed High Grade Cervical Squamous Intraepithelial Lesions. — 4; 1…

Primary: Dose Limiting Toxicity(DLT)/Significant Dose Delay of Paclitaxel With Cisplatin as Assessed by CTC 2.0 After 6 Cycles of Treatment — 0; 0; 2; 2 participants

Primary: Tumor Response — 1; 7; 17; 34 participants

Primary: Number of Patients With Dose-limiting Toxicities, as Assessed by CTCAE v 4.0 — 0 Participants

Primary: Number of Participants With Dose Limiting Toxicities (DLTs) — 0; 1; 0 Participants

Primary: Incidence of Objective Response — 32; 36; 30; 0 Participants — p=0.043

Primary: Response to Treatment Based on Response Evaluation Criteria in Solid Tumors (RECIST) Criteria (Evaluable Population) — 8; 7; 11; 6 participant

Primary: Progression-free Survival Greater Than 6 Months — 23.9 percentage of participants

Primary: Number of Patients With Measurable Concentration of Gemcitabine in Uterine Vein (dFdC) — 5 Participants

Primary: Objective Response Rate (PR or CR) — 0 percentage of evalubale patients

Primary: Histologic Regression — 40; 34.1 percentage of participants

Primary: Cervical HSIL — 46; 39 Participants — p=.29

Primary: Safety and Feasibility as Assessed by Number of Participants With Treatment-related Adverse Events — 5; 3; 8; 7 Participants

Primary: Anti-tumor Activity as Measured by Surviving Progression-free — 59 percentage of participants

Primary: Number of Seroconverted Subjects for Anti-human Papillomavirus (HPV)-16 and 18 Antibodies — 130; 4; 190; 5 Participants

Primary: Acceptability of Self-Collection Paired With Mobile Mammography — 33 Participants

Primary: Progression-Free Survival — 64.7 percentage of patients

Primary: Number of Histopathologically Confirmed Cervical Intraepithelial Neoplasia (CIN)2+ Cases Associated With HPV16 and/or HPV18 Infection Detected in the Preceding Cervical…

Primary: Progression-free Survival Greater Than 6 Months — 30; 5 participants

Primary: Number of Participants Who Scheduled or Completed Cervical Cancer Screening — 28; 21 Participants

Primary: Rate of Acute Grade 3/4 Toxicity (Excluding Grade 3 Leukopenia) — 81 percentage of participants

Primary: Cumulative Number of Participants Diagnosed by the Community Pathologist With Cervical Intraepithelial Neoplasia Grade 2 or Higher (CIN2+): "Community-based CIN2+"…

Primary: Number of Adverse Events, Graded According to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v4.0 — 56 Adverse Events

Primary: Patients With Objective Tumor Response Rate (Complete Response [CR] or Partial Response [PR]) Using RECIST Version 1.0 — 1; 16 participants

Primary: Safety and Toxicity — 0; 0; 0 Participants